Immunohistochemical expression of fatty acid synthase, Ki-67 and p53 in squamous cell carcinomas of the larynx.

Fatty acid synthase (FAS) is a recently discovered molecule involved in the energy supply to normal cells. FAS is overexpressed in neoplastic tissues because of their increased energy needs. We explored the immunohistochemical expression of FAS, Ki-67 and p53 in squamous cell carcinomas (SCC) of the larynx and their association with clinicopathological features and outcome. Specimens from 43 patients with SCC were evaluated. Statistical analysis revealed an association between poorly differentiated laryngeal carcinomas and FAS expression (p<0.005) and between FAS and Ki-67 overexpression (p<0.001). Finally, FAS expression was associated with overall survival (p<0.001). We suggest that FAS is a powerful prognostic indicator whose strength can be enhanced when it is evaluated together with clinicopathological data and Ki-67 expression.

[1]  I. Nishimoto,et al.  Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. , 2004, Oral oncology.

[2]  M. Loda,et al.  Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. , 2004, Oral oncology.

[3]  M. C. Archer,et al.  Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. , 2004, Carcinogenesis.

[4]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[5]  Suzuki Toshimitsu,et al.  Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  C. Bosman,et al.  Fatty acid synthase expression in melanoma , 2003, Journal of cutaneous pathology.

[7]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[8]  A. Nashimoto,et al.  Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach , 2002, Histopathology.

[9]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[10]  M. Gorospe,et al.  Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.

[11]  P. Visca,et al.  Immunohistochemical study of fatty acid synthase in ovarian neoplasms. , 2000, Oncology reports.

[12]  D. Heimburger,et al.  The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. , 2000, Human pathology.

[13]  T. Sugino,et al.  Fatty Acid Synthase Is Expressed Mainly in Adult Hormone-sensitive Cells or Cells with High Lipid Metabolism and in Proliferating Fetal Cells1 , 2000 .

[14]  F. Kuhajda.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. , 2000, Nutrition.

[15]  B. Oskouian.  Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. , 2000, Cancer letters.

[16]  W. Grizzle,et al.  Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue , 1999, Head & neck.

[17]  Joseph A. DiGiuseppe,et al.  Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. , 1998, Cancer research.

[18]  R. Kurman,et al.  Fatty acid synthase expression in endometrial carcinoma , 1998, Cancer.

[19]  Y. Furuya,et al.  Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. , 1997, Anticancer research.

[20]  J. Kalbfleisch,et al.  Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. , 1996, Human pathology.

[21]  G. Pasternack,et al.  Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.

[22]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[23]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Menéndez,et al.  In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells , 2005, Journal of cellular biochemistry.

[25]  Massimo Loda,et al.  Fatty acid synthase: A metabolic oncogene in prostate cancer? , 2004, Journal of cellular biochemistry.

[26]  P. Visca,et al.  Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. , 2003, Anticancer research.

[27]  E. Gabrielson,et al.  Increased fatty acid synthase is a therapeutic target in mesothelioma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  H. Kolb,et al.  Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. , 1986, Biological chemistry Hoppe-Seyler.